|  |
| --- |
| May 10, 2017Tim LangeHead of Investor RelationsPhone +49 201 177-3150tim.lange@evonik.com |
|  |

**Evonik Industries AG**

Rellinghauser Straße 1-11

45128 Essen

Germany

Phone +49 201 177-01

Fax +49 201 177-3475

www.evonik.com

**Supervisory Board**

Dr. Werner Müller, Chairman

**Executive Board**

Dr. Klaus Engel, Chairman

Christian Kullmann, Deputy Chairman

Dr. Ralph Sven Kaufmann

Thomas Wessel

Ute Wolf

Registered Office is Essen

Register Court Essen Local Court

Commercial Registry B 19474

**Evonik declares Force Majeure at C4 facilities in Antwerp and Marl**

Essen, Germany. Evonik declared Force Majeure for several C4 products from Antwerp, Belgium, and Marl, Germany, on Tuesday, May 9. This is the result of an explosion in the proximity of Evonik’s C4-plant at the Antwerp site on Sunday, May 7. Therefore, the plant in Antwerp was shut down. As a result, also the supply of raw materials necessary for C4 production in Marl, Germany, is affected.

Two employees were slightly injured. Both were taken to hospital for a medical check-up and were already discharged.

The precise extent of the damage and the duration of the production outage cannot yet be assessed. Evonik has insurance coverage for both technical and economic damage that will cover the vast majority of the damage.

Evonik will use all reasonable efforts to mitigate the effects of this situation on its customers.

The C4 plants in Antwerp and Marl produce intermediates like Butadiene, 1-Buten, MTBE and Isobutene for the tire, paper and plastic industries.

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world with more than 35,000 employees. In fiscal 2016 the enterprise generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.

**Disclaimer**

In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.